ReviewJournal of clinical medicine2023
Long-Term Use of Insomnia Medications: An Appraisal of the Current Clinical and Scientific Evidence.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 5 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Risks Associated With Benzodiazepine Long-Term Use in Chronic Insomnia: A Systematic Review and (Network) Meta-Analysis.Journal of sleep research · 2026Pooled it
- The effectiveness of digital therapeutics in improving sleep quality: a systematic review and network meta-analysis.BMC medicine · 2026Pooled it
- Short-term sleep benefitsFrontiers in pharmacology · 2026Pooled it
- Pooled it
- Tuina combined with other therapies for treating insomnia: a systematic review and network meta-analysis.Frontiers in neurologyPooled it
- Effect of diamine oxidase (DAO) enzyme dietary supplementation in subjects with insomnia symptoms and single nucleotide polymorphisms of theSleep medicine: X · 2026Article
- The Effects of Spiritual Interventions on Sleep Quality Among Patients with Chronic Diseases: A Systematic Review of Interventional Studies.Journal of religion and health · 2026Article
- Insomnia and associated pharmacological prescription in the adult population in primary care in Central Catalonia from 2018 to 2024.Family medicine and community health · 2026Observational
- The effect of acupuncture on hot flashes and sleep disturbances in women with breast cancer receiving endocrine therapy: a pre-post quasi-interventional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- The correlations between napping and subjective sleep and daytime functioning in Chinese insomnia patients: a large-scale real-world study.BMC psychiatry · 2026Article
- Comparative pharmacovigilance of non-benzodiazepine receptor agonists versus dual orexin receptor antagonists for insomnia in older adults.Frontiers in pharmacology · 2026Article
- Effect of Cervical Manual Therapy on Sleep Quality: A Scoping Review of Randomized Controlled Trials.Life (Basel, Switzerland) · 2025Review
- Greenspace proximity in relation to sleep health among a racially and ethnically diverse cohort of US women.Environmental research · 2025Article
- Association between sleep duration and disability in activities of daily living among Chinese older adults: a nationwide observational study.Frontiers in public health · 2025Observational
- Observational
- A scoping review of the effect of chronic stretch training on sleep quality in people with sleep disorders.European journal of applied physiology · 2024Article
- The effect of education regarding treatment guidelines for schizophrenia and major depressive disorders on psychiatrists' hypnotic medication prescribing behavior: a multicenter study.BMC psychiatry · 2024Article
- Analysis of the Improvement Sequence in Insomnia Symptoms and Factors Influencing the Treatment Outcomes of Smartphone-Delivered CBT in Patients with Insomnia Disorder.Nature and science of sleep · 2024Article
- Insomnia and Death Anxiety: A Theoretical Model with Therapeutic Implications.Journal of clinical medicine · 2023Article
- Pharmacists' Counseling and Benzodiazepines Dispensing for Sleep Disorders: A Simulated Patient Study in Iran.Journal of research in pharmacy practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While evidence supports the benefits of medications for the treatment of chronic insomnia, there is ongoing debate regarding their appropriate duration of use. A panel of sleep experts conducted a clinical appraisal regarding the use of insomnia medications, as it relates to the evidence supporting the focus statement, "No insomnia medication should be used on a daily basis for durations longer than 3 weeks at a time". The panelists' assessment was also compared to findings from a national survey of practicing physicians, psychiatrists, and sleep specialists. Survey respondents revealed a wide range of opinions regarding the appropriateness of using the US Food and Drug Administration (FDA)-approved medications for the treatment of insomnia lasting more than 3 weeks. After discussion of the literature, the panel unanimously agreed that some classes of insomnia medications, such as non-benzodiazepines hypnotics, have been shown to be effective and safe for long-term use in the appropriate clinical setting. For eszopiclone, doxepin, ramelteon and the newer class of dual orexin receptor antagonists, the FDA label does not specify that their use should be of a limited duration. Thus, an evaluation of evidence supporting the long-term safety and efficacy of newer non-benzodiazepine hypnotics is timely and should be considered in practice recommendations for the duration of pharmacologic treatment of chronic insomnia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.